# Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali

> **NCT02942277** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 301 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** Pfs25M-EPA
- **BIOLOGICAL:** Pfs230D1M-EPA
- **OTHER:** AS01
- **BIOLOGICAL:** Engerix-B
- **BIOLOGICAL:** Menactra
- **OTHER:** Normal Saline
- **DRUG:** Coartem

## Key facts

- **NCT ID:** NCT02942277
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-21
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02942277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02942277, "Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02942277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*